Company intelligence / Profile preview
Carrick Therapeutics
Boston, Massachusetts, United Statescarricktherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has two significant programs in clinical studies: CT7001 (oral CDK7 inhibitor) progressing through phase 1 studies, and CT900 which has shown clinical proof-of-concept in platinum-resistant ovarian cancer[5]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (CDK7 inhibitor, Folate Receptor Alpha targeted therapy)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Network of Pharma partners, clinicians, scientists, leading research institutes and hospitals[1]
Beyond the preview
Go deeper on Carrick Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carrick Therapeutics.